CHRISTINE DALE: Open Payments
NPI 1730782376 · GREENSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,319 in 153 payments from 24 companies in 2025. Trend: 2023 $2,567 · 2024 $2,834 · 2025 $3,319
Food & beverage: $3,301Consulting: $18
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $410 |
| Novartis Pharmaceuticals Corporation | 15 | $389 |
| ARS Pharmaceuticals Operations, Inc. | 17 | $344 |
| Regeneron Healthcare Solutions, Inc. | 13 | $308 |
| GENZYME CORPORATION | 11 | $291 |
| Amgen Inc. | 16 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $244 |
| GlaxoSmithKline, LLC. | 12 | $220 |
| ABBVIE INC. | 7 | $152 |
| CSL Behring | 5 | $133 |
Products named: DUPIXENT, TEZSPIRE, NEFFY, RINVOQ, XOLAIR, NEMLUVIO, TRELEGY ELLIPTA, NUCALA.
Industry payments across NC — which companies pay providers there.
